Clin2
NCT06471959Likely a fitRecruiting

Psychedelic group program for first responders with mental health issues

PsilocybinPsychotherapy, Group

Treatments studied

Part of Mental health clinical trials.

This study tests a group therapy program that includes a psychedelic medicine for first responders struggling with conditions like depression, anxiety, or PTSD. It is a 12-week program with mostly remote sessions and two in-person visits.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
32 people
Ages
19 years to 65 years
Study type
Interventional

Who can take part

  • You must be a current or former first responder (like police, firefighter, paramedic, volunteer, or retired).
  • You must be between 19 and 65 years old and have a BMI between 18.5 and 24.9.
  • You need a diagnosed mental health condition such as depression, anxiety, PTSD, OCD, grief, or stress-related disorder.
  • You must be willing to attend two in-person sessions and the rest remotely over this 12-week program.
  • Your current medications (if any) must have been at the same dose for at least the past 3 months, with no planned changes.
  • You must not have certain serious mental health disorders (like schizophrenia or bipolar) or recent use of other psychedelic drugs.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07566104Not yet recruiting· Phase 2
Group therapy with psilocybin for depression

This study tests whether psilocybin—a psychedelic compound—combined with group therapy can help people with depression. Participants receive guided psilocybin sessions at UCLA and attend group therapy to process the experience.

Los Angeles, California
NCT07506395Recruiting· Phase 1
Psilocybin group therapy for PTSD

This study tests if psilocybin-assisted group therapy can help people with moderate to severe PTSD. It is for veterans, first responders, female survivors of sexual violence, or Indigenous individuals.

Albuquerque, New Mexico
NCT07499583Not yet recruiting· Phase 1/Phase 2
Psilocybin therapy for depression and substance use in veterans and first responders

This trial tests whether psilocybin-assisted psychotherapy can help veterans and first responders with treatment-resistant depression and a co-occurring substance use disorder. It aims to see if this approach reduces depression and substance use.

Indianapolis, Indiana
NCT07565909Not yet recruiting· Phase 2
Psilocybin Therapy Retreat for Burned-Out Healthcare Workers

This study tests whether psilocybin (a psychedelic compound) given during a guided retreat can help healthcare clinicians who have lost meaning in their work and are experiencing depression. Participants will attend preparation sessions and a multi-day retreat where they receive psilocybin in a supportive group setting.

NCT06442423Recruiting· Phase 1
Psilocybin study for people with psychiatric symptoms

This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.

New Haven, Connecticut
NCT07745569Not yet recruiting· Phase 2
Psychedelic therapy study for depression or PTSD

This study tests whether electromagnetic brain stimulation and a psychedelic drug called psilocybin can help people with depression or PTSD. It aims to see how these treatments affect mood and behavior, and whether they are safe and helpful.

Hear when a new Psilocybin trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.